AK2 and cancer: Cancer-specific alleviation of AK2 expression was observed in 13 samples (93%), including cancers in clinical phase I (four cases), II (six cases) and III (three cases) phases, out of the 14 matched tissue sets and DUSP26 expression was lost in 57% of cancers (Fig. 6d,e).